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Why have two genes when one would suffice? Evolutionary pressure means that biology,
unlike government, is generally intolerant of wasted effort. Therefore, when multiple genes
exist presumably they are there to provide some benefit to the organism even if that benefit
is not immediately obvious to us scientists. A recent report from Raghu and colleagues
(Biosci. Rep. (2018) 38, pii: BSR20181690) [1] sheds some light on one possible reason
for the existence of two Phospholipases D genes in chordates when only one is present in
invertebrates.
Phospholipase Ds (PLDs) are phosphodiesterases that hydrolyze the diester phosphate bond of glyc-
erol phospholipids to produce phosphatidic acid and the corresponding lipid headgroup. In eukaryotes,
the best characterized enzymes of this type are selective for phosphatidylcholine. Budding yeast contain
a single PLD gene, which encodes an enzyme that has no discernible function during vegetative growth
(but can become essential when certain other genes involved in lipid metabolism are inactive), but that is
required for sporulation [2]. This function requires the catalytic activity of the enzyme, which is essential
for directing vesicular transport to form the membrane surrounding the nucleus of the nascent spore.
Mammalian genomes invariably contain two PLD genes termed PLD1 and PLD2 [3,4]. Although these
enzymes catalyze the same biochemical reactions and have largely overlapping expression patterns they
differ markedly in their subcellular localization and in the mechanisms by which their catalytic activities
are regulated [5]. In the accompanying paper, Raghu and colleagues conducted a phylogenetic analysis of
PLDhomologs revealing that the presumptive gene duplication that gave rise to PLD1 andPLD2happened
during the evolution of chordates. Insects contain a single PLD gene that appears closer to chordate PLD1
than to PLD2. InDrosophila, this single PLD gene is required for photoreceptor function and phototrans-
duction (light sensing) because this light-activated enzyme is required for integrity of the apical plasma
membrane and for recycling of vesicles to the apical plasma membrane after light-induced endocytosis.
These homozygous PLD-mutant Drosophila have no detectable PLD activity yet they develop normally
and have no discernable phenotype save the phototransduction defect discussed above [6].
This finding is broadly consistent with reports about PLD deficiency in other organisms where nor-
mal development and physiological functions are generally unimpaired but important phenotypes are
revealed in settings of stress and disease. For example, mice with deficiency of PLD1 exhibit defects in
platelet activation while inactivation of either PLD1 or PLD2 impairs some aspects of macrophage ac-
tivation and endocytosis [7]. Mice with genetic inactivation of both PLD1 and PLD2 are also viable but
exhibit defects in brain development and cognitive function [8]. These relatively underwhelming effects of
whole body PLD1 and PLD2 deficiency may reflect compensatory mechanisms [5]. The PLD lipid prod-
uct, phosphatidic acid, is widely implicated as the mediator of PLD-dependent signaling and regulatory
processes. Phosphatidic acid can be generated by de novo synthesis or the actions of diacylglycerol ki-
nases. Indeed, while budding, yeast lacking the single PLD have no phenotype during vegetative growth,
phenotypes are apparent when other genes involved in lipid synthesis and transport are also inactivated.
Further evidence that compensatory mechanisms blunt or mask phenotypes associated with PLD1 and
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PLD2 deficiency also comes from studies using acute genetic (RNA interference or over expression of inactive mu-
tants that may have dominant negative or interfering effects) or chemical biology approaches [9]. The latter of these
methods relied heavily on the unique ability of PLD to catalyze transphosphatidylation reactions using primary al-
cohols instead of water in the hydrolysis step of their catalytic cycle. This reaction generates phosphatidylalcohols
and both offers a way to monitor PLD activity and also an approach to attenuate PLD-dependent PA production.
Inhibitory effects of primarily alcohols (but not secondary alcohols which are not PLD substrates) inhibit multiple
cellular processes including vesicular transport, regulation of the actin cytoskeleton and cell growth. These processes
may therefore be regulated by PLD activity. This relatively unsophisticated approach has been superseded by the avail-
ability of potent selective small molecule PLD inhibitors in some cases with selectivity for PLD1 and PLD2. To some
extent, studies using these chemical tools have recapitulated and extended observations made using less sophisticated
approaches.
These efforts generally support the idea that PLD inhibition could be a useful therapeutic approach in settings
where PLD-dependent pathways are aberrantly up-regulated, for example cancer, thrombosis and neurodegenera-
tion. The fact that genetic deficiency of PLD is so well tolerated at least in animal models is certainly encouraging.
However, validation of PLD as a therapeutic target in these disease settings through studies of normal human genetic
variation or the identification of individuals with rare PLD-inactivating mutations is still lacking. More fundamen-
tally, the redundant and duplicate functions revealed in the above studies and the possibility that PLD deficiency can
be compensated for by alternative pathways for generation of PA raises important unanswered questions about the
significance of the presence of PLD1 and PLD2 genes in chordates
The PLD-deficientDrosophila described by Raghu and colleagues provide an appealing and uniquemodel system
to examine the functional differences between mammalian PLD1 and PLD2 by comparing their abilities to com-
plement the PLD-dependent phototransduction defect. This was accomplished by transgenic overexpression of the
mammalian enzymes using a reporter system that restricted expression to adult photoreceptor cells. When PLD1 was
overexpressed in wild-type Drosophila, this recapitulated the light-dependent retinal degradation observed with
overexpression of the single Drosophila PLD gene. However, this light-dependent retinal degeneration was not ob-
served with overexpression of PLD2 suggesting that PLD1 and PLD2 have different functions in this process. These
differences between PLD1 and PLD2 were further explored by evaluating their ability to complement genetic defi-
ciency of Drosophila PLD. In these experiments, PLD1 was able to completely suppress the light-dependent retinal
degeneration phenotype of Drosophila PLD mutants. Suppression of this phenotype was only partial and slower in
onset in Drosophila PLD mutants overexpressing PLD2. In mammalian cells, PLD1 and PLD2 exhibit distinct lo-
calization patterns. While PLD1 exhibits marked localization to intracellular membrane compartments, particularly
the Golgi apparatus PLD2 is localized predominantly to the plasmamembrane.Drosophila PLD localizes to a region
close to the plasmamembrane at the base of microvilli. PLD1 exhibited a broadly overlapping expression pattern with
Drosophila PLD, while PLD2 did not and was excluded from this region of the photoreceptors. Together these ob-
servations raise the possibility that different localization patterns contribute to or account for the differential abilities
of PLD1 and PLD2 to rescue Drosophila PLD deficiency.
PLD-catalyzed hydrolysis of phospholipids generates two products: the lipid head group and phosphatidic acid.
Although PLD enzymes with broader substrate selectivity are present in plants and some bacterial PLD1, PLD2 and
Drosophila PLD are phosphatidylcholine-specific enzymes. The water-soluble choline product is not considered
the primary PLD-generated signal. On the other hand, phosphatidic acids are implicated as signaling molecules with
targets that include protein kinases and small GTPase regulators andmay alter the properties of biologicalmembranes
to impact on membrane dynamics in settings that include vesicular transport or actin-dependent re-organization of
the plasma membrane during cell motility [10].
Phosphatidic acids can exhibit considerable structural diversity, primarily related to the length, saturation and
linkage of the radyl hydrocarbon chains. These are most commonly esterified fatty acids. These phosphatidic acid
responsive target molecules exhibit some selectivity for different phosphatidic acid molecular species at least in vitro.
Effects of phosphatidic acid on membrane structure, for example membrane curvature, also exhibit chain length
specific effects. For example, shorter chain phosphatidic acids may promote membrane curvature.
PLD1 and PLD2 exhibit some moderate selectivity for different phosphatidylcholine substrate molecular species
at least in vitro but despite the potential importance of this selectivity for PLD function, we know very little about
the substrate molecular species selectivity of PLD in vivo. To examine this possibility Raghu and colleagues devel-
oped HPLC-coupled tandemmass spectrometry methods that could detect and quantify different phosphatidic acid
molecular species. These methods rely on monitoring product ions generated by fragmentation of the corresponding
phosphatidic acid anions that correspond to loss of one of the acyl chains.
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Although this method cannot discriminate between sn1- and sn2-substituted fatty acids, it does allow deduction
of the chain length and saturation of the individual fatty acid substituents in the parent phosphatidic acid molecule.
Application of this approach revealed that PLD1 and PLD2 generated distinct patterns of phosphatidic acid molecu-
lar species and that the pattern of species restored by PLD1 expression inDrosophila PLDmutants was substantially
more similar to that observed in wild-type photoreceptors than that observed with overexpression of PLD2. The
mechanism responsible for these differences is not clear and may relate to the differential localization of PLD1 and
PLD2 with distinct phosphatidylcholine substrate rather than intrinsic differences in molecular species substrate se-
lectivity. However, this finding suggests that in addition to the differences in localization differences in molecular
species of phosphatidic acid might account for or contribute to the differential functions of PLD1 and PLD2 in com-
plementation of Drosophila PLD deficiency. More work is needed to examine these possibilities.
In summary, a presumptive gene duplication event that occurred early during the evolution of chordates generated
two PLD genes that encode proteins with the same enzymatic activity but differences in localization, regulation and
possibility substrate selectivity. While lower organisms, including Drosophila can function with a single PLD gene,
PLD1 and PLD2 are clearly not functionally redundant as evidenced by loss of function studies that include gene
knockouts and chemical inhibitors. This new report from Raghu and colleagues augments this work by suggesting
differences in localization and substrate selectivity may contribute to these functional differences between PLD1 and
PLD2. Because PLD1 and PLD2 deficiency is relatively well tolerated in mammals taken together, these findings
further support the concept that targeting PLD1 and PLD2 or their downstream signaling targets may be an effective
therapeutic approach in settings such as cardiovascular disease and cancerwhere PLD activity is elevated or aberrantly
regulated.
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